Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Rosacea - Overview
Rosacea - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Rosacea - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Rosacea - Companies Involved in Therapeutics Development
Accuitis Pharmaceuticals Inc
Aiviva BioPharma Inc
Alfasigma SpA
Amgen Inc
AOBiome LLC
Biomimetix JV LLC
Botanix Pharmaceuticals Ltd
Cellix Bio Pvt Ltd
Cutanea Life Sciences Inc
Dermata Therapeutics LLC
ELORAC Inc
Emeriti Pharma AB
Hovione FarmaCiencia SA
Maruho Co Ltd
Matrisys Bioscience Inc
Promius Pharma LLC
Sol-Gel Technologies Ltd
Sunny Pharmtech Inc
Tarsus Pharmaceuticals Inc
Timber Pharmaceuticals Inc
TWi Biotechnology Inc
Union Therapeutics AS
VYNE Therapeutics Inc
Rosacea - Drug Profiles
AC-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACUD-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AIV-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
B-244 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
benzoyl peroxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMX-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPX-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BTX-1702 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
carbamide peroxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLX-1621 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLXDER-621 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLXDER-622 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLXDER-623 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DMT-310 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
doxycycline hyclate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-0003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erenumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HY-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-1220 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
minocycline hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MSB-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
niclosamide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omigan pentahydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
phenylbutyrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rifaximin DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rosacea - Dormant Projects
Rosacea - Discontinued Products
Rosacea - Product Development Milestones
Featured News & Press Releases
Sep 10, 2020: Sol-Gel Technologies announces FDA acceptance for filing of New Drug Application for Epsolay for the treatment of inflammatory lesions of rosacea
Feb 13, 2020: Sol-Gel announces positive topline results from open-label, long-term safety study of Epsolay for treatment up to 52 Weeks
Jan 21, 2020: Sol-Gel announces presentation Epsolay at the 16th Annual Maui Derm for Dermatologists 2020 Meeting
Dec 09, 2019: Botanix initiates BTX 1702 rosacea study
Oct 16, 2019: Sol-Gel to present on potential of Sol-Gel Microencapsulation Technology in Rosacea at 39th Annual Fall Clinical Dermatology Conference
Sep 20, 2019: Hovione announces successful end-of-phase 2 meeting with the FDA and outlines phase 3 program for minocycline topical gel
Jul 08, 2019: Sol-Gel announces positive top-line results from epsolay phase 3 program in papulopustular Rosacea
Jun 26, 2019: BioPharmX reports positive results from BPX-041 trial for rosacea
May 22, 2019: BioPharmX announces last patient visit in Phase 2b trial of BPX-04 for papulopustular rosacea
Mar 04, 2019: BioPharmX completes enrollment in phase 2b trial of BPX-04 for patients with papulopustular rosacea
Oct 12, 2018: BioPharmX enrols first subject in Phase llb trial of BPX-04
Sep 25, 2018: Sol-Gel Technologies Announces 50% Enrollment in Pivotal Phase III Epsolay Program for the Treatment of Papulopustular Rosacea
Aug 01, 2018: BioPharmX secures IRB approval to start Phase ll trial of BPX-04
Jun 18, 2018: Sol-Gel Technologies Initiates Pivotal Phase III Clinical Program for Papulopustular Rosacea
May 24, 2018: BioPharmX Studies Show Hydrophilic Topical Minocycline Gel May Be the Preferred Treatment Option for Rosacea Patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Rosacea, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development for Rosacea, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Rosacea - Pipeline by Accuitis Pharmaceuticals Inc, H2 2020
Rosacea - Pipeline by Aiviva BioPharma Inc, H2 2020
Rosacea - Pipeline by Alfasigma SpA, H2 2020
Rosacea - Pipeline by Amgen Inc, H2 2020
Rosacea - Pipeline by AOBiome LLC, H2 2020
Rosacea - Pipeline by Biomimetix JV LLC, H2 2020
Rosacea - Pipeline by Botanix Pharmaceuticals Ltd, H2 2020
Rosacea - Pipeline by Cellix Bio Pvt Ltd, H2 2020
Rosacea - Pipeline by Cutanea Life Sciences Inc, H2 2020
Rosacea - Pipeline by Dermata Therapeutics LLC, H2 2020
Rosacea - Pipeline by ELORAC Inc, H2 2020
Rosacea - Pipeline by Emeriti Pharma AB, H2 2020
Rosacea - Pipeline by Hovione FarmaCiencia SA, H2 2020
Rosacea - Pipeline by Maruho Co Ltd, H2 2020
Rosacea - Pipeline by Matrisys Bioscience Inc, H2 2020
Rosacea - Pipeline by Promius Pharma LLC, H2 2020
Rosacea - Pipeline by Sol-Gel Technologies Ltd, H2 2020
Rosacea - Pipeline by Sunny Pharmtech Inc, H2 2020
Rosacea - Pipeline by Tarsus Pharmaceuticals Inc, H2 2020
Rosacea - Pipeline by Timber Pharmaceuticals Inc, H2 2020
Rosacea - Pipeline by TWi Biotechnology Inc, H2 2020
Rosacea - Pipeline by Union Therapeutics AS, H2 2020
Rosacea - Pipeline by VYNE Therapeutics Inc, H2 2020
Rosacea - Dormant Projects, H2 2020
Rosacea - Dormant Projects, H2 2020 (Contd..1), H2 2020
Rosacea - Discontinued Products, H2 2020